Early endosomal abnormalities and cholinergic neuron degeneration in Amyloid-β protein precursor transgenic mice

Journal of Alzheimer's Disease

Volumn 34, Issue 3, 2013, Pages 691-700

  Choi, Jennifer H K ^a,b   Kaur, Gurjinder ^a   Mazzella, Matthew J ^a   Morales Corraliza, Jose ^a,b   Levy, Efrat ^a,b   Mathews, Paul M ^a,b  

^a NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; amyloid protein precursor; cholinergic neurons; endocytosis; endosomes; septal nuclei

Indexed keywords

AMYLOID PRECURSOR PROTEIN; RAB PROTEIN;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL POPULATION; CHOLINERGIC NERVE CELL; COMPARATIVE STUDY; CONTROLLED STUDY; ENDOSOME; FEMALE; GENE MUTATION; GENE OVEREXPRESSION; MALE; MOUSE; NERVE CELL DEGENERATION; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; GENETICS; HUMAN; METABOLISM; NERVE DEGENERATION; PATHOLOGY; UPREGULATION;

AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; CHOLINERGIC NEURONS; ENDOSOMES; FEMALE; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NERVE DEGENERATION; UP-REGULATION;

EID: 84876376191     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-122143     Document Type: Article

References (57)

1. Cataldo AM, Peterhoff CM, Troncoso JC, Gomez-Isla T, Hyman BT, Nixon RA (2000) Endocytic pathway abnormalities precede amyloid - deposition in sporadic Alzheimer's disease and Down syndrome: Differential effects of APOE genotype and presenilin mutations. Am J Pathol 157, 277- 286. (Pubitemid 30641743)
2. Di Paolo G, Kim TW (2011) Linking lipids to Alzheimer's disease: Cholesterol and beyond. Nat Rev Neurosci 12, 284- 296.
3. Burns MP, Rebeck GW(2010) Intracellular cholesterol homeostasis and amyloid precursor protein processing. Biochim Biophys Acta 1801, 853-859.
4. Liu JP, Tang Y, Zhou S, Toh BH, McLean C, Li H (2010) Cholesterol involvement in the pathogenesis of neurodegenerative diseases. Mol Cell Neurosci 43, 33-42.
5. Rogaeva E, Kawarai T, George-Hyslop PS (2006) Genetic complexity of Alzheimer's disease: Successes and challenges. J Alzheimers Dis 9, 381-387. (Pubitemid 44253332)
6. Cataldo AM, Petanceska S, Peterhoff CM, Terio NB, Epstein CJ, Villar A, Carlson EJ, Staufenbiel M, Nixon RA (2003) App gene dosage modulates endosomal abnormalities of Alzheimer's disease in a segmental trisomy 16 mouse model of down syndrome. J Neurosci 23, 6788-6792. (Pubitemid 36951206)
7. Jiang Y, Mullaney KA, Peterhoff CM, Che S, Schmidt SD, Boyer-Boiteau A, Ginsberg SD, Cataldo AM, Mathews PM, Nixon RA (2010) Alzheimer's-related endosome dysfunction in Down syndrome is Aβ-independent but requires APP and is reversed by BACE-1 inhibition. Proc Natl Acad Sci U S A 107, 1630-1635.
8. Cataldo AM, Mathews PM, Boiteau AB, Hassinger LC, Peterhoff CM, Jiang Y, Mullaney K, Neve RL, Gruenberg J, Nixon RA (2008) Down syndrome fibroblast model of Alzheimer-related endosome pathology: Accelerated endocytosis promotes late endocytic defects. Am J Pathol 173, 370-384.
9. Thomas RS, Lelos MJ, Good MA, Kidd EJ (2011) Clathrinmediated endocytic proteins are upregulated in the cortex of the Tg2576 mouse model of Alzheimer's disease-like amyloid pathology. Biochem Biophys Res Commun 415, 656-661.
10. Goate AM (1998) Monogenetic determinants of Alzheimer's disease: APP mutations. Cell Mol Life Sci 54, 897-901. (Pubitemid 28461677)
11. Mullan M, Crawford F, Axelman K, Houlden H, Lilius L, Winblad B, Lannfelt L (1992) A pathogenic mutation for probable Alzheimer's disease in the APP gene at the Nterminus of -amyloid. Nat Genet 1, 345-347.
12. Goate A, Chartier-Harlin MC, Mullan M, Brown J, Crawford F, Fidani L, Giuffra L, Haynes A, Irving N, James L, et al. (1991) Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 349, 704-706. (Pubitemid 21912142)
13. Ginsberg SD, Mufson EJ, Alldred MJ, Counts SE, Wuu J, Nixon RA, Che S (2011) Upregulation of select rab GTPases in cholinergic basal forebrain neurons in mild cognitive impairment and Alzheimer's disease. J Chem Neuroanat 42, 102-110.
14. Howe CL, MobleyWC (2004) Signaling endosome hypothesis: A cellular mechanism for long distance communication. J Neurobiol 58, 207-216. (Pubitemid 38173719)
15. Whitehouse PJ, Price DL, Clark AW, Coyle JT, DeLong MR (1981) Alzheimer disease: Evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol 10, 122-126. (Pubitemid 11053099)
16. Mufson EJ, Counts SE, Perez SE, Ginsberg SD(2008) Cholinergic system during the progression of Alzheimer's disease: Therapeutic implications. Expert Rev Neurother 8, 1703- 1718.
17. Ginsberg SD, Che S, Wuu J, Counts SE, Mufson EJ (2006) Down regulation of trk but not p75NTR gene expression in single cholinergic basal forebrain neurons mark the progression of Alzheimer's disease. J Neurochem 97, 475-487.
18. Mufson EJ, Ginsberg SD, Ikonomovic MD, DeKosky ST (2003) Human cholinergic basal forebrain: Chemoanatomy and neurologic dysfunction. J Chem Neuroanat 26, 233-242. (Pubitemid 38077147)
19. Mufson EJ, Counts SE, Fahnestock M, Ginsberg SD (2007) Cholinotrophic molecular substrates of mild cognitive impairment in the elderly. Curr Alzheimer Res 4, 340-350. (Pubitemid 47416626)
20. Wu C, Cui B, He L, Chen L, Mobley WC (2009) The coming of age of axonal neurotrophin signaling endosomes. J Proteomics 72, 46-55.
21. Beattie EC, Zhou J, Grimes ML, Bunnett NW, Howe CL, Mobley WC (1996) A signaling endosome hypothesis to explain NGF actions: Potential implications for neurodegeneration. Cold Spring Harb Symp Quant Biol 61, 389-406. (Pubitemid 27257988)
22. Sofroniew MV, Howe CL, MobleyWC (2001) Nerve growth factor signaling, neuroprotection, and neural repair. Annu Rev Neurosci 24, 1217-1281. (Pubitemid 32695259)
23. Nixon RA (2005) Endosome function and dysfunction in Alzheimer's disease and other neurodegenerative diseases. Neurobiol Aging 26, 373-382. (Pubitemid 40082721)
24. Nixon RA, CataldoAM,MathewsPM(2000) The endosomallysosomal system of neurons in Alzheimer's disease pathogenesis: A review. Neurochem Res 25, 1161-1172.
25. Mathews PM, Jiang Y, Schmidt SD, Grbovic OM, Mercken M, Nixon RA (2002) Calpain activity regulates the cell surface distribution of amyloid precursor protein: Inhibition of calpains enhances endosomal generation of β-cleaved Cterminal APP fragments. J Biol Chem 277, 36415-36424.
26. Boncristiano S, Calhoun ME, Kelly PH, Pfeifer M, Bondolfi L, Stalder M, Phinney AL, Abramowski D, Sturchler-Pierrat C, Enz A, Sommer B, Staufenbiel M, Jucker M (2002) Cholinergic changes in the APP23 transgenic mouse model of cerebral amyloidosis. J Neurosci 22, 3234-3243. (Pubitemid 35379210)
27. Bronfman FC, Moechars D, Van Leuven F (2000) Acetylcholinesterase- positive fiber deafferentation and cell shrinkage in the septohippocampal pathway of aged amyloid precursor protein london mutant transgenic mice. Neurobiol Dis 7, 152-168. (Pubitemid 30451031)
28. Van Dam D, Marescau B, Engelborghs S, Cremers T, Mulder J, Staufenbiel M, De Deyn PP (2005) Analysis of cholinergic markers, biogenic amines, and amino acids in the CNS of two APP overexpression mouse models. Neurochem Int 46, 409-422. (Pubitemid 40292721)
29. Kaur G, Mohan P, Pawlik M, DeRosa S, Fajiculay J, Che S, Grubb A, Ginsberg SD, Nixon RA, Levy E (2010) Cystatin C rescues degenerating neurons in a cystatin B-knockout mouse model of progressive myoclonus epilepsy. Am J Pathol 177, 2256-2267.
30. Granholm AC, Ford KA, Hyde LA, Bimonte HA, Hunter CL, Nelson M, Albeck D, Sanders LA, Mufson EJ, Crnic LS (2002) Estrogen restores cognition and cholinergic phenotype in an animal model of Down syndrome. Physiol Behav 77, 371-385. (Pubitemid 35373893)
31. West MJ (1993) New stereological methods for counting neurons. Neurobiol Aging 14, 275-285. (Pubitemid 23214693)
32. Gundersen HJ, Bagger P, Bendtsen TF, Evans SM, Korbo L, Marcussen N, Moller A, Nielsen K, Nyengaard JR, Pakkenberg B, et al. (1988) The new stereological tools: Disector, fractionator, nucleator and point sampled intercepts and their use in pathological research and diagnosis. APMIS 96, 857- 881.
33. Choi JH, Berger JD, Mazzella MJ, Morales-Corraliza J, Cataldo AM, Nixon RA, Ginsberg SD, Levy E, Mathews PM (2009) Age-dependent dysregulation of brain amyloid precursor protein in the Ts65Dn Down syndrome mouse model. J Neurochem 110, 1818-1827.
34. Morales-Corraliza J, Mazzella MJ, Berger JD, Diaz NS, Choi JH, Levy E, Matsuoka Y, Planel E, Mathews PM (2009) In vivo turnover of tau and APP metabolites in the brains of wild-type and Tg2576 mice: Greater stability of sAPP in the β-amyloid depositing mice. PLoS One 4, e7134.
35. Sturchler-Pierrat C, Abramowski D, Duke M, Wiederhold KH, Mistl C, Rothacher S, Ledermann B, Burki K, Frey P, Paganetti PA, Waridel C, Calhoun ME, Jucker M, Probst A, Staufenbiel M, Sommer B (1997) Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci U S A 94, 13287-13292. (Pubitemid 27518514)
36. Cataldo A, Rebeck GW, Ghetri B, Hulette C, Lippa C, Van Broeckhoven C, van Duijn C, Cras P, Bogdanovic N, Bird T, Peterhoff C, Nixon R (2001) Endocytic disturbances distinguish among subtypes of Alzheimer's disease and related disorders. Ann Neurol 50, 661-665. (Pubitemid 33021925)
37. Cataldo AM, Barnett JL, Pieroni C, Nixon RA (1997) Increased neuronal endocytosis and protease delivery to early endosomes in sporadic Alzheimer's disease: Neuropathologic evidence for a mechanism of increased β-amyloidogenesis. J Neurosci 17, 6142-6151. (Pubitemid 27329890)
38. Moechars D, Dewachter I, Lorent K, Reverse D, Baekelandt V, Naidu A, Tesseur I, Spittaels K, Haute CV, Checler F, Godaux E, Cordell B, Van Leuven F (1999) Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain. J Biol Chem 274, 6483-6492. (Pubitemid 29111064)
39. Salehi A, Delcroix JD, Belichenko PV, Zhan K,Wu C,Valletta JS, Takimoto-Kimura R, Kleschevnikov AM, Sambamurti K, Chung PP, XiaW,Villar A, CampbellWA,Kulnane LS, Nixon RA, Lamb BT, Epstein CJ, Stokin GB, Goldstein LS, Mobley WC (2006) Increased App expression in a mouse model of Down's syndrome disrupts NGF transport and causes cholinergic neuron degeneration. Neuron 51, 29-42. (Pubitemid 43963336)
40. Cooper JD, Salehi A, Delcroix JD, Howe CL, Belichenko PV, Chua-Couzens J, Kilbridge JF, Carlson EJ, Epstein CJ, Mobley WC (2001) Failed retrograde transport of NGF in a mouse model of Down's syndrome: Reversal of cholinergic neurodegenerative phenotypes following NGF infusion. Proc Natl Acad Sci U S A 98, 10439-10444. (Pubitemid 32803038)
41. Davies P, Maloney AJ (1976) Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 2, 1403. (Pubitemid 8004505)
42. Coyle JT, Price DL, DeLongMR(1983) Alzheimer's disease: A disorder of cortical cholinergic innervation. Science 219, 1184-1190. (Pubitemid 13160659)
43. Perry EK, Johnson M, Kerwin JM, Piggott MA, Court JA, Shaw PJ, Ince PG, Brown A, Perry RH (1992) Convergent cholinergic activities in aging and Alzheimer's disease. Neurobiol Aging 13, 393-400.
44. Granholm AC, Sanders LA, Crnic LS (2000) Loss of cholinergic phenotype in basal forebrain coincides with cognitive decline in a mouse model of Down's syndrome. Exp Neurol 161, 647-663. (Pubitemid 30137022)
45. Bellucci A, Luccarini I, Scali C, Prosperi C, Giovannini MG, Pepeu G, Casamenti F (2006) Cholinergic dysfunction, neuronal damage and axonal loss in TgCRND8 mice. Neurobiol Dis 23, 260-272. (Pubitemid 44080837)
46. Apelt J, Kumar A, Schliebs R (2002) Impairment of cholinergic neurotransmission in adult and aged transgenic Tg2576 mouse brain expressing the Swedish mutation of human β- amyloid precursor protein. Brain Res 953, 17-30. (Pubitemid 35217803)
47. German DC, Yazdani U, Speciale SG, Pasbakhsh P, Games D, Liang CL (2003) Cholinergic neuropathology in a mouse model of Alzheimer's disease. J Comp Neurol 462, 371-381. (Pubitemid 36775900)
48. Aucoin JS, Jiang P, Aznavour N, Tong XK, Buttini M, Descarries L, Hamel E (2005) Selective cholinergic denervation, independent from oxidative stress, in a mouse model of Alzheimer's disease. Neuroscience 132, 73-86. (Pubitemid 40380716)
49. Christensen DZ, Bayer TA, Wirths O (2010) Intracellular Ass triggers neuron loss in the cholinergic system of the APP/PS1KI mouse model of Alzheimer's disease. Neurobiol Aging 31, 1153-1163.
50. Kar S, Quirion R (2004) Amyloid - peptides and central cholinergic neurons: Functional interrelationship and relevance to Alzheimer's disease pathology. Prog Brain Res 145, 261-274. (Pubitemid 37442949)
51. Geula C, Nagykery N, Nicholas A,WuCK(2008) Cholinergic neuronal and axonal abnormalities are present early in aging and in Alzheimer disease. J Neuropathol Exp Neurol 67, 309- 318. (Pubitemid 351507486)
52. Pericak-Vance MA, Haines JL (1995) Genetic susceptibility to Alzheimer disease. Trends Genet 11, 504-508.
53. Rovelet-Lecrux A, Hannequin D, Raux G, Le Meur N, Laquerriere A, Vital A, Dumanchin C, Feuillette S, Brice A, Vercelletto M, Dubas F, Frebourg T, Campion D (2006) APP locus duplication causes autosomal dominant earlyonset Alzheimer disease with cerebral amyloid angiopathy. Nat Genet 38, 24-26. (Pubitemid 43011878)
54. Sleegers K, Brouwers N, Gijselinck I, Theuns J, Goossens D, Wauters J, Del-Favero J, Cruts M, van Duijn CM, Van Broeckhoven C (2006) APP duplication is sufficient to cause early onset Alzheimer's dementia with cerebral amyloid angiopathy. Brain 129, 2977-2983. (Pubitemid 44684518)
55. Cirrito JR, Kang JE, Lee J, Stewart FR, Verges DK, Silverio LM, Bu G, Mennerick S, HoltzmanDM(2008) Endocytosis is required for synaptic activity-dependent release of amyloid-β in vivo. Neuron 58, 42-51. (Pubitemid 351467029)
56. Cirrito JR, Yamada KA, Finn MB, Sloviter RS, Bales KR, May PC, Schoepp DD, Paul SM,Mennerick S, HoltzmanDM (2005) Synaptic activity regulates interstitial fluid amyloid-β levels in vivo. Neuron 48, 913-922. (Pubitemid 41814696)
57. Kalvodova L, Kahya N, Schwille P, Ehehalt R, Verkade P, Drechsel D, Simons K (2005) Lipids as modulators of proteolytic activity of BACE: Involvement of cholesterol, glycosphingolipids, and anionic phospholipids in vitro. J Biol Chem 280, 36815-36823. (Pubitemid 41587762)